- Home
- CAPR vs SITC Comparison
CAPR vs SITC Comparison
Compare CAPR & SITC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CAPR
- SITC
- Stock Information
- Founded
- CAPR 2005
- SITC 1965
- Country
- CAPR United States
- SITC United States
- Employees
- CAPR N/A
- SITC N/A
- Industry
- CAPR Biotechnology: Biological Products (No Diagnostic Substances)
- SITC Real Estate Investment Trusts
- Sector
- CAPR Health Care
- SITC Real Estate
- Exchange
- CAPR Nasdaq
- SITC Nasdaq
- Market Cap
- CAPR 867.6M
- SITC 830.0M
- IPO Year
- CAPR N/A
- SITC 1993
- Fundamental
- Price
- CAPR $13.07
- SITC $15.46
- Analyst Decision
- CAPR Strong Buy
- SITC Hold
- Analyst Count
- CAPR 7
- SITC 10
- Target Price
- CAPR $39.29
- SITC $39.03
- AVG Volume (30 Days)
- CAPR 1.8M
- SITC 1.7M
- Earning Date
- CAPR 11-13-2024
- SITC 02-11-2025
- Dividend Yield
- CAPR N/A
- SITC 4.20%
- EPS Growth
- CAPR N/A
- SITC 757.51
- EPS
- CAPR N/A
- SITC 13.71
- Revenue
- CAPR $23,228,045.00
- SITC $451,683,000.00
- Revenue This Year
- CAPR N/A
- SITC N/A
- Revenue Next Year
- CAPR $74.85
- SITC N/A
- P/E Ratio
- CAPR N/A
- SITC $1.13
- Revenue Growth
- CAPR 65.33
- SITC N/A
- 52 Week Low
- CAPR $3.52
- SITC $14.84
- 52 Week High
- CAPR $23.40
- SITC $64.44
- Technical
- Relative Strength Index (RSI)
- CAPR 37.42
- SITC 38.49
- Support Level
- CAPR $12.25
- SITC $15.26
- Resistance Level
- CAPR $20.75
- SITC $15.69
- Average True Range (ATR)
- CAPR 1.62
- SITC 0.36
- MACD
- CAPR -0.24
- SITC 0.15
- Stochastic Oscillator
- CAPR 9.65
- SITC 59.13
About CAPR Capricor Therapeutics Inc.
Capricor Therapeutics Inc is a biotechnology company focused on advancing transformative cell and exosome-based therapeutics to redefine the treatment landscape for rare diseases. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat and prevent a wide range of diseases with targeted delivery.
About SITC SITE Centers Corp.
SITE Centers Corp is a United States-based self-administered and self-managed REIT that operates as a fully integrated real estate company. The company is engaged in the business of owning, leasing, acquiring, redeveloping, developing and managing shopping centers.